NCT01561027 is a Phase 2 clinical trial of CNV1014802 in Lumbosacral Radiculopathy, sponsored by Biogen.

Who is sponsoring NCT01561027?

NCT01561027 is sponsored by Biogen.

What drugs are being tested in NCT01561027?

Interventions in NCT01561027: CNV1014802, Placebo.

What condition does NCT01561027 study?

NCT01561027 studies Lumbosacral Radiculopathy.

Is NCT01561027 still recruiting?

NCT01561027 is currently completed. Last updated 13 October 2017.

Last reviewed 2017-10-13 · How we verify

NCT01561027

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Crossover Study of CNV1014802 in Subjects With Neuropathic Pain From Lumbosacral Radiculopathy

Completed Phase 2 Last updated 13 October 2017

What this trial tests

Phase 2 trial testing CNV1014802 in Lumbosacral Radiculopathy in 82 participants. Completed in 31 August 2012.

Timeline

30 April 2011

Primary endpoint
30 June 2012

31 August 2012

Quick facts

Lead sponsor	Biogen
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	triple
Primary purpose	treatment
Enrollment	82
Start date	30 April 2011
Primary completion	30 June 2012
Estimated completion	31 August 2012
Sites	12 locations across Denmark, France, Sweden, Czechia

Drugs / interventions tested

CNV1014802 — full drug profile →
Placebo

Conditions studied

Lumbosacral Radiculopathy — all drugs for Lumbosacral Radiculopathy →

Sponsor

Biogen — full company profile →

Who can join

Adults 18 to 65, any sex, with Lumbosacral Radiculopathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is a randomized, double blind, cross-over study to evaluate the safety and efficacy of CNV1014802 in subjects with neuropathic pain from lumbosacral radiculopathy.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Nav1.7 and other voltage-gated sodium channels as drug targets for pain relief.
Emery EC, Luiz AP, Wood JN. · · 2016 · cited 152× · PMID 26941184 · DOI 10.1517/14728222.2016.1162295
Inhibition of Na<sub>V</sub>1.7: the possibility of ideal analgesics.
Kitano Y, Shinozuka T. · · 2022 · cited 13× · PMID 36092147 · DOI 10.1039/d2md00081d
Effects of a State- and Use-Dependent Nav1.7 Channel Blocker on Ambulatory Blood Pressure: A Randomized, Controlled Crossover Study.
Fong R, Ballow CH, Naik H, Steiner D, et al · · 2019 · cited 5× · PMID 30144099 · DOI 10.1002/jcph.1298

Verify or expand the search:

Other trials of CNV1014802

Trials testing the same drug.

NCT02551497 — Study to Evaluate the Interaction Between a Drug and CNV1014802 in Healthy Subjects · Phase 1 · completed
NCT02359344 — PK & Tolerability of CNV1014802 in Young and Elderly Healthy Volunteers · Phase 1 · completed
NCT01540630 — A Phase IIa Withdrawal Study of CNV1014802 in Patients With Trigeminal Neuralgia · Phase 2 · completed

Other recruiting trials for Lumbosacral Radiculopathy

Currently open trials in the same condition.

NCT07498140 — Procedural Framing and Epidural Steroid Injection Outcomes · NA · recruiting
NCT07264270 — Study to Evaluate Safety of C-1101 Versus Sterile Saline in Adults With Chronic Painful Lumbosacral Radiculopathy · Phase 1 · recruiting
NCT05613569 — A Long-term, 3-Year, Follow-up Study for Patients Completing the KS-GIG-001-01 Study · active not recruiting

Other Biogen trials

Trials by the same sponsor.

NCT07483632 — A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses · Phase 3 · not yet recruiting
NCT06628687 — A Study to Learn How BIIB141 (Omaveloxolone) Affects the Health of Participants With Friedrich's Ataxia Who Took it Duri · recruiting
NCT07444450 — A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy · Phase 3 · not yet recruiting
NCT07444489 — A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants · Phase 3 · not yet recruiting
NCT07444476 — A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years Wit · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01561027 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Biogen
Last refreshed: 13 October 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01561027.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing